🔎 Trials Near Me

ホーム › 大腸癌 › アイオワ州

アイオワ州における大腸癌の臨床試験

アイオワ州内の拠点で、大腸癌に関する15件の研究が参加者を募集しています。

アイオワ州内の都市

公式研究テキスト(英語)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf
  • Mercy Cancer Center-West Lakes, Clive
  • 他8件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT05673148

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mary Greeley Medical Center, Ames
  • McFarland Clinic - Ames, Ames
  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • 他12件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Family Communications After Genetic Testing

  • Mercy Cancer Center-West Lakes, Clive
  • Mercy Medical Center - Des Moines, Des Moines
  • Mercy Medical Center-West Lakes, West Des Moines
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07143487

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • University of Iowa Hospitals and Clinics, Iowa City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06324357

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

  • University of Iowa Hospitals and Clinics, Iowa City
  • Mission Cancer Blood, Waukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06750094

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  • University of Iowa Hospital, Iowa City
  • Mission Cancer Blood, Waukee
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06662786

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists - Council Bluffs, Council Bluffs
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07750158

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  • University of Iowa Hospital and Clinics, Iowa City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07284849

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • University of Iowa Health Care, Iowa City
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05283330

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

  • University of Iowa Hospitals & Clinics, Iowa City
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/08更新 · NCT06026410

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • Saint Anthony Regional Hospital, Carroll
  • Physicians' Clinic of Iowa PC, Cedar Rapids
  • 他15件
被験者募集中第3相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/03/31更新 · NCT07018869

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
  • University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf
  • Physicians' Clinic of Iowa PC, Cedar Rapids
  • 他10件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

  • The University of Iowa - Ankeny, Ankeny
  • Saint Anthony Regional Hospital, Carroll
  • Physicians' Clinic of Iowa PC, Cedar Rapids
  • 他8件
被験者募集中観察研究
60歳以上 · 全性別 · 2026/01/08更新 · NCT03998202

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。